Introducing The New Purdue Pharma
This article was originally published in Scrip
Executive Summary
Mark Timney has been president and CEO of US specialty company Purdue Pharma for just over two years but he's playing a long game to pull the business away from its single-track R&D model towards other opportunities outside pain therapy – its mainstay development area
You may also be interested in...
Purdue Signs Two Deals To Diversify Portfolio
Purdue Pharma has made headway this month on its 2016-initiated plans to diversify the company's R&D portfolio away from the pain therapy space, having actioned two collaborative deals with Exicure and AnaBios.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.